Saturday, July 12, 2014 Last update: 12:33 AM
FreshNews.com - All Company Technology News Since 1996

IMPAX Laboratories, Inc.

News articles for IMPAX Laboratories, Inc.:

Wednesday, July 2, 2014

  • Impax Acquires Two Products from Actavis
    HAYWARD, Calif., July 2, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has acquired from Actavis plc (NYSE: ACT) two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed. The acquisition ... read more

Tuesday, July 1, 2014

Friday, June 6, 2014

Monday, May 12, 2014

  • Impax Laboratories to Present at Upcoming Investor Conferences
    HAYWARD, Calif., May 12, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will present at two upcoming investor conferences in May. Bank of America Merrill Lynch 2014 Health Care ConferenceImpax will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, ... read more

Thursday, May 1, 2014

  • Impax Laboratories Reports First Quarter 2014 Results
    HAYWARD, Calif., May 1, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today reported adjusted net income of $16.5 million, or $0.24 per diluted share for the first quarter ended March 31, 2014, compared to adjusted net income of $25.3 million, or $0.37 per diluted share in the prior year ... read more

Monday, April 21, 2014

  • Impax Board of Directors Appoints G. Frederick Wilkinson President and CEO
    HAYWARD, Calif., April 21, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its Board of Directors has appointed G. Frederick Wilkinson as Impax's President and Chief Executive Officer effective April 29, 2014. Mr. Wilkinson, who previously served as President, Actavis Global Research and Development ... read more

Wednesday, April 16, 2014

  • Impax Launches Authorized Generic RENVELA┬«
    HAYWARD, Calif., April 16, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it is commencing shipment of authorized generic RENVELA (sevelamer carbonate 800 mg tablets), through Global Pharmaceuticals, Impax's generics division. RENVELA is indicated for the control of serum phosphorus in patients with chronic ... read more

Friday, April 11, 2014

Monday, April 7, 2014

Wednesday, April 2, 2014

Wednesday, February 26, 2014

Thursday, February 20, 2014

Friday, January 24, 2014

Tuesday, January 14, 2014